This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction뇌경색증을 유발하지 않은 대뇌동맥의 폐쇄 및 협착

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I66 (Occlusion and stenosis of cerebral arteries not resulting in cerebral infarction) | Special Copayment Reduction: V191 (cerebrovascular disease special copayment reduction: 5% copayment for up to 30 days from the registration date)
B. SynonymsIntracranial atherosclerosis, intracranial arterial stenosis (ICAS), middle cerebral artery stenosis (MCA stenosis), basilar artery stenosis
C. Adult onsetOccurs in middle-aged and older adults and shows markedly higher prevalence in Asian, African, and Hispanic populations. A major cause of ischemic stroke worldwide.
1. HistoryIntracranial atherosclerotic stenosis was recognized after the development of cerebral angiography in the mid-20th century, and the WASID and SAMMPRIS clinical trials played a decisive role in establishing treatment guidelines.
2. CausesIntracranial arterial atherosclerosis is the most common cause, and vascular dissection, vessel-invading tumors, radiation vasculopathy, and certain drugs (cocaine, etc.) are also causes.
3. GeneticsALDH2 and ABCG8 gene variants and several GWAS loci are associated with susceptibility to intracranial atherosclerosis in East Asians.
4. General epidemiologyAbout 8–10% of ischemic strokes worldwide are due to intracranial atherosclerosis, and in Asians the proportion of intracranial atherosclerosis is higher than that of extracranial atherosclerosis.
5. PathophysiologyThree mechanisms—perforator occlusion (occlusion of the penetrating artery ostium), artery-to-artery embolism, and distal hypoperfusion—cause ischemia due to intracranial stenosis.
6. SymptomsTIA or minor stroke symptoms corresponding to the territory supplied by the stenotic vessel may occur repeatedly, and some cases are asymptomatic.
7. SignsSpecific neurological deficits depending on the stenotic vessel appear, such as hemiplegia, sensory disturbance, language disturbance, and cerebellar signs.
8. ScreeningAfter TIA or stroke, a systematic etiologic evaluation including intracranial vascular imaging is essential.
9. DiagnosisStenosis is assessed noninvasively with MRA or CTA, its hemodynamic significance is determined by brain perfusion studies, and it is confirmed by DSA.
10. TreatmentDual antiplatelet therapy (aspirin + clopidogrel), high-intensity statins, and intensive risk factor management are the foundation, and intracranial angioplasty or stenting is considered in selected cases.
11. PrognosisIn 70–99% intracranial stenosis, the annual stroke risk reaches 10–15% even with medical treatment, and the higher the degree of stenosis, the poorer the prognosis.
12. PreventionIntensive control of blood pressure, diabetes, and hyperlipidemia, smoking cessation, weight management, and antiplatelet therapy are key to slowing the progression of intracranial atherosclerosis and preventing stroke.
13. ReferencesChimowitz MI, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. NEJM. 2005 … and 9 other papers

1. History

Clinical understanding of stenosis and occlusion of the intracranial cerebral arteries began with the development of cerebral angiography in the mid-20th century. With the clinical introduction of cerebral angiography in the 1940s–50s, it became possible to visualize stenosis and occlusion of intracranial arteries such as the middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and basilar artery (BA) during life. During this period, the clinical observation that intracranial atherosclerosis is particularly common in Asian and African patients first began to be systematized.

In the 1990s, with the clinical spread of MRA and CTA enabling noninvasive intracranial vascular evaluation, the epidemiology of intracranial arterial stenosis (ICAS) began to be studied in earnest. The 1995 WASID (Warfarin-Aspirin Symptomatic Intracranial Disease) study was a large study comparing the effects of warfarin and aspirin in patients with symptomatic intracranial stenosis; it showed that warfarin was not superior to aspirin and carried a higher bleeding risk, putting a brake on the general use of warfarin. The SAMMPRIS (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis) study, published in 2011, showed that intracranial endovascular stenting (Wingspan stent) had no significant benefit over aggressive medical management (aspirin + clopidogrel + intensive risk factor management) and in fact carried a higher early stroke risk, playing a decisive role in shifting the treatment of intracranial stenosis toward aggressive medical management.

Recently, high-resolution vessel wall MRI has drawn attention as a new noninvasive tool for evaluating atherosclerotic plaque characteristics, inflammatory activity, and vascular remodeling in intracranial arteries. This technology goes beyond simple assessment of luminal stenosis to distinguish unstable from stable plaques and contributes to individualizing treatment strategies for patients at high stroke risk. Because intracranial atherosclerotic stroke accounts for a considerable portion of all ischemic strokes in East Asia, including Korea, research in this field has become an especially important area of cerebrovascular medicine in Korea.


2. Causes

The most common cause of intracranial cerebral artery stenosis is intracranial atherosclerosis. Compared with extracranial vessels, intracranial vessels have a thinner adventitia, no vasa vasorum, and less vascular smooth muscle, so the pattern of vascular remodeling during plaque formation differs. Major risk factors for intracranial atherosclerosis include hypertension, diabetes, dyslipidemia, smoking, obesity, and metabolic syndrome, of which hypertension and diabetes act as particularly strong independent risk factors. Racial differences are also marked: in Asian, African, and Hispanic populations, the proportion of intracranial atherosclerosis is prominent relative to extracranial atherosclerosis.

Nonatherosclerotic causes include intracranial arterial dissection, which occurs particularly in the vertebral and basilar arteries and can arise from trauma, connective tissue disorders, or spontaneously. Vascular stenosis due to intracranial arterial dissection is characterized on MRI vessel wall imaging by crescent-shaped vessel wall thickening and intramural hematoma. Reversible cerebral vasoconstriction syndrome (RCVS) causes transient intracranial vascular stenosis due to spastic vasoconstriction and may be accompanied by recurrent thunderclap headaches and cortical SAH or infarction. Vasoconstrictive drugs such as cocaine, amphetamines, ergotamine, and 5-HT agonists are also important triggers of RCVS.

Radiation vasculopathy is vascular stenosis that develops years to decades after head and neck radiation therapy; its mechanism is endothelial injury, fibrosis, and accelerated atherosclerosis of vessels within the radiation field. Primary angiitis of the CNS (PACNS) is a granulomatous vasculitis confined to intracranial vessels that causes stenosis, occlusion, and cerebral infarction. Moyamoya disease is a special vascular disease characterized by progressive stenosis-occlusion of the distal bilateral internal carotid arteries and the origins of the anterior and middle cerebral arteries, and it is an important nonatherosclerotic cause of intracranial cerebral artery stenosis.


3. Genetics

The genetic background of intracranial atherosclerosis is partly shared with extracranial atherosclerosis but has race-specific differences. The ALDH2 (aldehyde dehydrogenase 2) gene variant (rs671, ALDH2*2) is common in East Asians and is reported to increase the risk of intracranial atherosclerosis by increasing oxidative stress along with acetaldehyde accumulation when drinking alcohol. This variant has drawn attention as a genetic risk factor for intracranial atherosclerotic stroke, especially in Korean, Chinese, and Japanese people.

Genome-wide association studies (GWAS) have reported ABCG8 (related to reverse cholesterol transport), LPA (lipoprotein(a) gene, a strong risk factor for atherothrombosis), and APOA5 (apolipoprotein A5, triglyceride regulation) as loci associated with intracranial atherosclerosis. Variants in lipid metabolism-related genes (LDLR, APOB, PCSK9) also contribute indirectly to the risk of intracranial atherosclerosis. Polymorphisms in blood pressure regulation genes (CYP11B2, AGT, ACE) affect both small and large intracranial vessels through predisposition to hypertension.

As the genetic basis of moyamoya disease, the p.R4810K (rs112735431) variant of the RNF213 gene has been identified as the susceptibility gene most strongly associated in East Asians, and this variant is found in about 95% of Japanese patients with moyamoya disease. RNF213 is an E3 ubiquitin ligase presumed to be involved in regulating vascular smooth muscle cell function. The genetic predisposition to primary angiitis of the CNS has not been fully elucidated, but some associations with HLA gene complex variants have been reported.


4. General epidemiology

Intracranial atherosclerotic stenosis (ICAS) accounts for about 8–10% of ischemic strokes worldwide and is clinically very important because the recurrence rate of stroke due to intracranial atherosclerosis is high. Racial differences are marked: the proportion of intracranial atherosclerotic stroke is 2–4 times higher in Asian (Korean, Chinese, Japanese), African, and Hispanic populations than in White people. This is associated with the tendency in Asians for atherosclerosis to concentrate in intracranial rather than extracranial vessels and with the high prevalence of hypertension and diabetes.

According to Korean stroke registry data, intracranial atherosclerosis-related stroke accounts for about 20–30% of all ischemic strokes, a markedly higher proportion than in Western countries. The annual prevalence of ICAS is proportional to the burden of stroke risk factors and is high in people aged 70 or older and in patients with combined hypertension and diabetes. In the WASID study, the 1-year stroke recurrence rate in patients with 70–99% symptomatic intracranial stenosis was about 25%, showing how high the recurrence risk of intracranial atherosclerosis is. This risk fell to 12.2% at 1 year with intensive medical treatment in the SAMMPRIS study but remains considerably high.

In ICAS, the perforator occlusion mechanism, in which the ostium of a penetrating artery (perforator) is occluded by plaque, is important, and the resulting lacunar infarction is a common form of intracranial atherosclerotic stroke in East Asia. The MCA M1 segment, basilar artery, and intracranial segment of the vertebral artery are the most common sites of ICAS. The prevalence of ICAS is slightly higher in men than in women, but there are also reports that prognosis is poorer in women.


5. Pathophysiology

The ischemic mechanisms of intracranial cerebral artery stenosis are classified into three. First is the perforator occlusion mechanism, in which a stenotic plaque protruding laterally directly occludes the ostium of a perforating artery or induces thrombosis within the perforating artery, causing small deep infarcts. This mechanism is most common in MCA M1 stenosis and appears as lacunar infarcts of the basal ganglia, internal capsule, and thalamus. Second is the artery-to-artery embolism mechanism, in which, after rupture of an unstable plaque, platelet thrombi or thrombus fragments embolize distally, causing cortical infarction.

Third is the distal hypoperfusion mechanism, in which severe stenosis (70% or more) lowers distal perfusion pressure, and border zone ischemia occurs when additional hemodynamic stress such as a drop in blood pressure or reduced cardiac output is applied in the absence of sufficient collateral circulation. This mechanism is more common particularly in basilar artery stenosis or multivessel stenosis and appears in the form of recurrent TIAs. In practice, multiple mechanisms often act in combination in a single patient, and the dominant mechanism can be inferred by analyzing the infarct pattern on DWI MRI.

The characteristics of atherosclerotic plaque formation in intracranial vessels differ somewhat from those of extracranial vessels. Intracranial vessels have a thin adventitia and no vasa vasorum, so they receive oxygen directly through the lumen. As a result, intracranial plaques tend to grow mainly inward (concentric), which means that compensatory outward vascular expansion (compensatory remodeling) is limited. In vessel wall MRI studies, luminal-side contrast enhancement (luminal enhancement) of intracranial plaques suggests active inflammation and instability and has been reported to be strongly associated with recent stroke or TIA.


6. Symptoms

The clinical symptoms of intracranial cerebral artery stenosis are determined by the territory supplied by the stenotic vessel. To be classified as I66, there must by definition be no cerebral infarction, so this corresponds to transient ischemic attack (TIA) or a state of complete recovery from a minor neurological deficit. In middle cerebral artery (MCA) stenosis, contralateral hemiplegia or hemiparesis, hemisensory abnormalities, speech disturbance (with dominant hemisphere involvement), hemineglect (with nondominant hemisphere involvement), and hemianopia appear transiently and then resolve.

In basilar artery (BA) stenosis, dizziness, nausea, vomiting, diplopia, eye movement abnormalities, gait ataxia, and bilateral limb weakness appear, and recurrent posterior circulation TIAs are particularly characteristic of high-risk basilar artery stenosis. A 'TIA crescendo' (repeated TIAs within a short period) occurring with basilar artery stenosis is a dangerous warning sign immediately before progression to complete occlusion and requires emergency management. In stenosis of the intracranial segment of the vertebral artery (V4 segment), Wallenberg-like symptoms may appear transiently.

Asymptomatic intracranial stenosis also exists and is discovered incidentally on MRA or CTA performed for other reasons. Even in asymptomatic ICAS, when accompanied by cerebral small vessel disease burden (white matter degeneration, silent small infarcts), it may present as vascular cognitive impairment in which cognitive decline, memory loss, and gait disturbance progress slowly. As stenosis progresses, headache (hemodynamic headache), transient monocular blindness (related to the anterior cerebral artery), or symptom fluctuation with postural changes may appear.


7. Signs

Neurological examination findings in patients with intracranial cerebral artery stenosis may be normal if complete recovery has occurred after TIA. However, careful examination sometimes reveals reflex asymmetry, mild motor asymmetry, subtle sensory abnormalities, or mild decline on cognitive function tests. After repeated TIAs, neurological deficits may not fully recover, so it is important not to miss them on examination.

Specific signs on physical examination directly suggesting intracranial stenosis are rare. However, when signs of generalized atherosclerosis such as carotid bruit, decreased lower extremity pulses (peripheral artery disease), or retinal arterial narrowing (hypertensive retinopathy) are present, the likelihood of intracranial atherosclerosis is high. Persistently high systolic blood pressure on measurement indicates the need for management of intracranial atherosclerosis risk factors. In moyamoya disease, lethargy, reduced motivation, and decreased concentration due to frontal lobe ischemia may appear gradually.

In neurovascular ultrasound, transcranial Doppler (TCD) is used to evaluate intracranial blood flow noninvasively. On TCD, increased mean flow velocity in the stenotic vessel (MCA > 80 cm/s, basilar artery > 50 cm/s) and decreased velocity downstream of the stenosis suggest significant stenosis. In addition, detection of microembolic signals (MES) using TCD helps assess embolic activity from unstable plaques. The current degree of neurological deficit is quantified with the NIHSS, and cognitive function is assessed with the MMSE, MoCA, and others.


8. Screening

General population screening for intracranial cerebral artery stenosis is not recommended. However, after TIA or minor stroke, a systematic etiologic evaluation including intracranial vascular imaging is essential. Promptly confirming intracranial vascular stenosis with MRA or CTA is important for decisions on secondary prevention treatment. When small vessel disease burden suggestive of intracranial atherosclerosis (white matter degeneration, silent small infarcts) is found on MRI, adding intracranial vascular evaluation (MRA) in that patient is recommended.

In high-risk groups (multiple atherosclerotic risk factors, Asian ancestry, history of previous stroke), intracranial vascular evaluation can be considered more actively. In patients with confirmed intracranial atherosclerosis, assessment of hemodynamic reserve (cerebrovascular reserve, CVR) using brain perfusion MRI (PWI) or CT perfusion and transcranial Doppler (TCD) helps identify high-risk patients. When CVR is reduced, the risk of ischemia with a drop in blood pressure or postural change is high, so it is important to adjust blood pressure targets and avoid orthostatic hypotension.

When moyamoya disease is suspected (recurrent anterior or posterior circulation TIAs, especially in children or young adults), MRA is checked for progressive stenosis of the terminal internal carotid artery and the MCA origin and for the characteristic puff-of-smoke collateral vessels at the base of the brain, and the diagnosis is confirmed by DSA. Vessel wall MRI is playing an increasingly important role in distinguishing intracranial atherosclerosis, dissection, and vasculitis.


9. Diagnosis

In the noninvasive diagnosis of intracranial cerebral artery stenosis, MR angiography (MRA) is used first. Time-of-flight (TOF) MRA can evaluate the major intracranial vessels without contrast and has high sensitivity for detecting stenosis of 50% or more. However, TOF MRA can overestimate the degree of stenosis due to signal loss from turbulent flow, so caution is needed in interpretation. Contrast-enhanced MRA compensates for this drawback and allows more accurate assessment of stenosis.

CT angiography (CTA) can accurately evaluate intracranial vascular stenosis with a short scan time and high spatial resolution and can confirm the presence of calcification. CTA is useful in emergencies because vascular evaluation and brain perfusion evaluation can be performed simultaneously. High-resolution vessel wall MRI (VW-MRI) is performed on 3T MRI and is useful for distinguishing unstable plaques by evaluating the location of intracranial plaques (eccentric vs concentric), contrast enhancement (active inflammation), intraplaque hemorrhage, lipid core, and so on. Recent studies have confirmed that plaques showing strong contrast enhancement are more strongly associated with stroke recurrence.

Digital subtraction angiography (DSA) is the standard test for diagnosing intracranial stenosis, but because it is invasive, it is performed when MRA or CTA is inconclusive or when planning endovascular treatment. The degree of stenosis is calculated according to the WASID criteria, with 50% or more classified as significant stenosis and 70% or more as high-risk stenosis. Brain perfusion studies (MRI PWI or CT perfusion) are used to assess the hemodynamic significance of the stenotic site and to quantify CVR. Flow velocity measurement and MES detection using TCD are also used as adjuncts to assess the instability of intracranial stenosis.


10. Treatment

Based on the SAMMPRIS study results, the first-line treatment for symptomatic intracranial stenosis (50–99%) is aggressive medical management. The key is taking dual antiplatelet therapy (aspirin 325 mg + clopidogrel 75 mg) for at least 90 days, followed by maintenance on a single antiplatelet agent. In the SAMMPRIS study, the 30-day stroke rate under this treatment was markedly lower in the medical group at 5.8% compared with 14.7% in the stent group, demonstrating the superiority of medical management. Lowering LDL cholesterol to below 70 mg/dL (below 55 mg/dL if possible) with high-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg) is recommended.

Intensive management of risk factors is the core of medical treatment. The targets applied in the intensive medical management group of the SAMMPRIS study were LDL <70 mg/dL, systolic blood pressure <140 mmHg (<130 mmHg in patients with diabetes or CKD), BMI <25 kg/m², HbA1c <7% in diabetes, smoking cessation and alcohol abstinence, and regular exercise. Such multifactorial intensive management is far more important than simple drug prescription. In the WASID study, warfarin offered no benefit over aspirin and only increased bleeding risk, so it is not recommended in intracranial atherosclerosis unless there is a concomitant cardioembolic cause for which anticoagulation is clearly advantageous.

Intracranial angioplasty and stenting (intracranial PTA/stenting) is generally not recommended after SAMMPRIS, but it may be performed selectively by experienced physicians in extremely high-risk patients (recurrent TIA or stroke despite aggressive medical management, or confirmed hemodynamic hypoperfusion). Endovascular treatment of basilar artery occlusion or severe stenosis has shown some benefit in studies such as BASILAR but has not yet been established as standard. In moyamoya disease, cerebral revascularization surgery (direct or indirect bypass) is effective in preventing ischemia.


11. Prognosis

The prognosis of intracranial cerebral artery stenosis differs greatly according to the degree of stenosis, location, hemodynamic significance, and presence of symptoms. In the WASID study, the 1-year stroke recurrence rate in patients with 50–99% symptomatic intracranial stenosis reached about 25%. In the SAMMPRIS study, the 1-year stroke recurrence rate fell to 12.2% under intensive medical management but remains high. With 70–99% stenosis, the recurrence risk is about twice that of 50–69% stenosis. Prognosis is poorer when hemodynamic reserve (CVR) is reduced and when the infarct pattern is border zone or perforator.

In patients with intracranial stenosis, the risk of recurrent stroke includes not only infarction at the stenotic site but also cardioembolism and cerebral infarction in other territories. Patients with intracranial atherosclerosis have a high rate of concomitant coronary artery disease (myocardial infarction, unstable angina), and cardiovascular events are also important prognostic determinants. SAMMPRIS confirmed that intensive medical management (statins, dual antiplatelet therapy, risk factor management) can lower the 2-year stroke rate from 14.9% to 9.7%. Treatment adherence is very important to prognosis, and continued use of statins and antiplatelet agents is key to improving long-term prognosis.

The stroke risk in asymptomatic intracranial stenosis is lower than in symptomatic stenosis but still higher than in the general population. When white matter lesions or silent small infarcts are present, the risk of progression to vascular cognitive impairment increases, so early detection and aggressive risk factor management are needed. Moyamoya disease carries a very high risk of recurrent stroke due to progressive stenosis without appropriate revascularization surgery, and even after surgery, regular MRI and MRA follow-up every 6 months to 1 year is recommended.


12. Prevention

Primary prevention of intracranial atherosclerotic stenosis is intensive management of atherosclerotic risk factors. Treatment of hypertension is the most important single preventive measure; maintaining systolic blood pressure below 130 mmHg slows the progression of atherosclerosis in both small and large intracranial vessels. Glycemic control (HbA1c below 7%) prevents endothelial injury and accelerated atherosclerosis due to diabetes. High-intensity statin therapy lowers LDL cholesterol and stabilizes atherosclerotic plaques, contributing to stroke prevention, and high-intensity statins are essential particularly after intracranial atherosclerotic stroke.

Smoking cessation is the most effective behavioral intervention for slowing atherosclerosis progression and restoring endothelial function. Smoking promotes platelet aggregation and causes vasoconstriction, markedly increasing the risk of intracranial vascular stenosis and occlusion. Appropriate exercise (30 minutes of moderate aerobic exercise at least 5 days a week) exerts combined vascular protective effects through blood pressure control, improved blood glucose, improved lipid profile, and enhanced endothelial function. A Mediterranean diet and a low-salt diet have positive effects on blood pressure and lipids, and because heavy drinking causes elevated blood pressure and atherosclerosis progression, moderation of alcohol intake is recommended.

In secondary prevention (preventing recurrence), maintenance on a single antiplatelet agent after 90 days of dual antiplatelet therapy, high-intensity statins, and thorough blood pressure and glucose management should continue. When hemodynamic hypoperfusion is confirmed, excessive lowering of blood pressure should be avoided (in patients with reduced CVR, overly low blood pressure can actually worsen ischemia), and attention should be paid to orthostatic hypotension. Progression of stenosis is monitored through regular neurological follow-up and MRA/MRI.


13. References

  1. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316. DOI: 10.1056/NEJMoa043033. PMID: 15800226.

  2. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003. DOI: 10.1056/NEJMoa1105335. PMID: 21899409.

  3. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39(8):2396-2399. DOI: 10.1161/STROKEAHA.107.505776. PMID: 18535284.

  4. Kim JS, Nah HW, Park SM, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke. 2012;43(12):3313-3318. DOI: 10.1161/STROKEAHA.112.658500. PMID: 23033344.

  5. Huang YN, Gao S, Li SW, et al. Vascular lesions in Chinese patients with transient ischemic attacks. Neurology. 1997;48(2):524-525. DOI: 10.1212/wnl.48.2.524. PMID: 9040747.

  6. Qureshi AI, Caplan LR. Intracranial atherosclerosis. Lancet. 2014;383(9921):984-998. DOI: 10.1016/S0140-6736(13)61088-0. PMID: 24007975.

  7. Baik SH, Jung C, Kim BJ, et al. Intracranial atherosclerosis-related infarction in patients with acute large vessel occlusion: prevalence and clinical outcomes. J Stroke. 2020;22(2):215-225. DOI: 10.5853/jos.2019.03365. PMID: 32418393.

  8. Klein IF, Lavallée PC, Mazighi M, et al. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study. Stroke. 2010;41(7):1405-1409. DOI: 10.1161/STROKEAHA.110.585992. PMID: 20498428.

  9. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299. DOI: 10.1001/archneur.1969.00480090076012. PMID: 5775283.

  10. Bae HJ, Lee J, Park JM, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis. 2007;24(4):355-360. DOI: 10.1159/000107702. PMID: 17717372.